within Pharmacolibrary.Drugs.ATC.N;

model N01AX11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.00013583333333333335,
    adminDuration  = 600,
    adminMass      = 4500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.012,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N01AX11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sodium oxybate is the sodium salt of gamma-hydroxybutyric acid (GHB), a central nervous system depressant primarily used in the treatment of narcolepsy, particularly for cataplexy and excessive daytime sleepiness. It is approved for medical use as an orphan drug in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of sodium oxybate.</p><h4>References</h4><ol><li><p>Felmlee, MA, et al., &amp; Morris, ME (2021). γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology. <i>The AAPS journal</i> 23(1) 22–None. DOI:<a href=\"https://doi.org/10.1208/s12248-020-00543-z\">10.1208/s12248-020-00543-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33417072/\">https://pubmed.ncbi.nlm.nih.gov/33417072</a></p></li><li><p>Borgen, LA, et al., &amp; Scharf, MB (2004). The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. <i>Journal of clinical pharmacology</i> 44(3) 253–257. DOI:<a href=\"https://doi.org/10.1177/0091270003262795\">10.1177/0091270003262795</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14973300/\">https://pubmed.ncbi.nlm.nih.gov/14973300</a></p></li><li><p>Chen, C, et al., &amp; Skowronski, R (2021). Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in two open-label, randomized, crossover studies. <i>Clinical and translational science</i> 14(6) 2278–2287. DOI:<a href=\"https://doi.org/10.1111/cts.13087\">10.1111/cts.13087</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34121333/\">https://pubmed.ncbi.nlm.nih.gov/34121333</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N01AX11;
